Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
We evaluated 121 patients with follicular lymphoma (FL) and analyzed the association between the soluble interleukin-2 receptor (sIL-2R) level at diagnosis and the cumulative incidence of transformation. By a receiver-operating characteristic analysis, we determined a cutoff value of sIL-2R for transformation at 4360 U/mL to classify patients into two groups. Patients in the high sIL-2R group showed a shorter progression-free survival (PFS) and shorter disease-specific survival (DSS) (p < 0.001 and p = 0.018). Furthermore, the cumulative incidence of transformation in the high sIL-2R group was higher than that in the low sIL-2R group (40.9% vs. 7.3% at 5 years, p < 0.001). In a multivariate analysis, high sIL-2R was an independent predictive risk factor for transformation (HR 7.42, 95% CI: 2.75-20.0, p < 0.001). This study showed that the sIL-2R level at diagnosis may be a prognostic factor for transformation, PFS, and DSS in patients with FL.
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kento
K
Umino
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Shin-Ichiro
SI
Fujiwara
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Shoko
S
Ito
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kiyomi
K
Mashima
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Daisuke
D
Minakata
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Hirofumi
H
Nakano
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Ryoko
R
Yamasaki
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Yasufumi
Y
Kawasaki
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Miyuki
M
Sugimoto
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Masahiro
M
Ashizawa
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kaoru
K
Hatano
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kiyoshi
K
Okazuka
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kazuya
K
Sato
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Iekuni
I
Oh
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Ken
K
Ohmine
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Takahiro
T
Suzuki
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Kazuo
K
Muroi
a Department of Medicine, Division of Hematology , Jichi Medical University , Tochigi , Japan.
Yoshinobu
Y
Kanda
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002471:Cell Transformation, Neoplastic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012189:Retrospective Studies; D012307:Risk Factors
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2
Follicular lymphoma; soluble interleukin-2 receptor; transformation